Itraconazol Alter

Itraconazole, the active ingredient in Itraconazol Alter, is a Triazole antifungal presented as an oral formulation for oral use. It treats a range of superficial and systemic fungal infections in adults and children as prescribed.

GNH USA supplies Itraconazol Alter as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is a triazole antifungal used to manage fungal infections affecting various organ systems. - Blastomycosis: achieves clinical cure and prevents disease progression. - Histoplasmosis: helps eradicate systemic infection. - Aspergillosis: controls invasive disease. - Candidiasis: treats severe or refractory infections. - Superficial mycoses: resolves skin and nail fungal infections.

Adverse reactions to itraconazole can vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Rash: skin erythema or pruritus. - Taste disturbance: altered or loss of taste. - Abdominal pain: intermittent discomfort. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe allergic reactions: anaphylaxis or angioedema. - Cardiac failure: worsening of pre‑existing heart conditions. - QT prolongation: risk of arrhythmias. - Stevens‑Johnson syndrome: severe skin detachment. - Hepatic necrosis: rare but life‑threatening liver damage.

When prescribing itraconazole, clinicians should observe several safety measures. - Liver function monitoring: assess baseline and periodic liver enzymes. - Drug interaction review: evaluate concomitant medications for CYP3A4 effects. - Cardiac assessment: check QT interval in patients with cardiac risk. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Itraconazole interacts with several medicines through metabolic pathways.

Major Interactions (Avoid): - Rifampin: markedly reduces itraconazole plasma concentrations. - Ketoconazole: additive hepatotoxic potential. - St. John’s wort: induces metabolism, lowering efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may increase itraconazole levels. - CYP3A4 substrates (e.g., statins): risk of increased toxicity. - Antacids or proton‑pump inhibitors: may decrease absorption of itraconazole.